The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Human Reproduction Update

• Publication date

  1997-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/HUMUPD/3.3.255PMID 9322101
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ovarian hyperstimulation syndrome: pre-ovulatory serum concentrations of interleukin-6, interleukin-1 receptor antagonist and tumour necrosis factor-alpha cannot predict its occurrence.

  1996cited by this paper
• Endocrinology: Ovarian hyperstimulation syndrome: pre-ovulatory serum concentrations of interleukin-6, interleukin-1 receptor antagonist and tumour necrosis factor-α cannot predict its occurrence

  1996cited by this paper
• Characterization of intraperitoneal cytokines and nitrites in women with severe ovarian hyperstimulation syndrome.

  1996cited by this paper
• Plasma inflammatory cytokines correlate to the ovarian hyperstimulation syndrome.

  1996cited by this paper
• Vascular endothelial growth factor localization in human ovary and fallopian tubes: possible role in reproductive function and ovarian cyst formation.

  1996cited by this paper
• Vascular endothelial growth factor expression in cycling human endometrium.

  1996cited by this paper
• Endocrinology and paracrinology Interleukin-8 concentration in peritoneal fluid of patients with endometriosis and modulation of interleukin-8 expression in human mesothelial cells

  1996cited by this paper
• Endocrinology: Plasma inflammatory cytokines correlate to the ovarian hyperstimulation syndrome

  1996cited by this paper
• Vascular permeability factor and vascular endothelial growth factor in ovarian hyperstimulation syndrome: a preliminary report.

  1996cited by this paper
• Elevated interleukin‐6 levels in the ovarian hyperstimulation syndrome: ovarian immunohistochemical localization of interleukin‐6 signal

  1996cited by this paper
• Vascular endothelial growth factor (VEGF) concentrations are elevated in peritoneal fluid of women with endometriosis.

  1996cited by this paper
• Interleukin-2 and ovarian hyperstimulation syndrome: a pilot study.

  1995cited by this paper
• Increased capillary permeability induced by human follicular fluid: A hypothesis for an ovarian origin of the hyperstimulation syndrome

  1995cited by this paper
• [Ovarian hyperstimulation syndrome].

  1995cited by this paper
• Inhibition of ovarian-derived prorenin to angiotensin cascade in the treatment of ovarian hyperstimulation syndrome.

  1995cited by this paper
• Endocrinology: Inhibition of ovarian-derived prorenin to angiotensin cascade in the treatment of ovarian hyperstimulation syndrome

  1995cited by this paper
• Increased capillary permeability induced by human follicular fluid: a hypothesis for an ovarian origin of the hyperstimulation syndrome

  1995cited by this paper
• Decreased incidence of severe ovarian hyperstimulation syndrome in high risk in-vitro fertilization patients receiving intravenous albumin: a prospective study.

  1995cited by this paper
• Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome.

  1995cited by this paper
• Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells. Role in corpus luteum development.

  1995cited by this paper
• Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome.

  1994cited by this paper
• Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis.

  1994cited by this paper
• The ascites in the ovarian hyperstimulation syndrome does not originate from the ovary.

  1993cited by this paper
• Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor.

  1993cited by this paper
• Management of Severe Ovarian Hyperstimulation Syndrome by Ascitic Fluid Aspiration and Intensive Intravenous Fluid Therapy

  1993cited by this paper
• High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis.

  1993cited by this paper
• Does elective cryopreservation of all embryos from women at risk of ovarian hyperstimulation syndrome reduce the incidence of the condition?

  1993cited by this paper
• The use of intravenous albumin in patients at high risk for severe ovarian hyperstimulation syndrome.

  1993cited by this paper
• Vascular permeability factor (VPF, VEGF) in tumor biology

  1993cited by this paper
• Elevated levels of interleukin-6 in ascites and serum from women with ovarian hyperstimulation syndrome.

  1993cited by this paper
• Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

  1993cited by this paper
• CLINICAL REPORT: The use of intravenous albumin in patients at high risk for severe ovarian hyperstimulation syndrome

  1993cited by this paper
• Vascular endothelial growth factor (VEGF) messenger ribonucleic acid (mRNA) expression in luteinized human granulosa cells in vitro.

  1993cited by this paper
• Identification and localization of alternately spliced mRNAs for vascular endothelial growth factor in human uterus and estrogen regulation in endometrial carcinoma cell lines.

  1993cited by this paper
• Outcome of treatment subsequent to the elective cryopreservation of all embryos from women at risk of the ovarian hyperstimulation syndrome.

  1992cited by this paper
• Concentrations of immunoreactive interleukin-1 and interleukin-2 in human preovulatory follicular fluid.

  1992cited by this paper
• Luteal phase support and severe ovarian hyperstimulation syndrome.

  1992cited by this paper
• Autotransfusion of the ascitic fluid in the treatment of severe ovarian hyperstimulation syndrome.

  1992cited by this paper
• Cytokine serum level during severe sepsis in human IL-6 as a marker of severity.

  1992cited by this paper
• Ovarian hyperstimulation syndrome after superovulation using GnRH agonists for IVF and related procedures.

  1992cited by this paper
• Follicular aspiration does not protect against the development of ovarian hyperstimulation syndrome

  1992cited by this paper
• Vascular endothelial growth factor messenger ribonucleic acid expression in the primate ovary.

  1992cited by this paper
• Negative inotropic effects of cytokines on the heart mediated by nitric oxide.

  1992cited by this paper
• Ovarian hyperstimulation syndrome: A review of pathophysiology

  1992cited by this paper
• The correlation between interleukin 2 and soluble interleukin 2 receptors to oestradiol, progesterone and testosterone levels in periovulatory follicles of in-vitro fertilization patients.

  1992cited by this paper
• Molecular and biological properties of the vascular endothelial growth factor family of proteins.

  1992cited by this paper
• Detection of interleukin-6 in human follicular fluid.

  1992cited by this paper
• Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk groups.

  1991cited by this paper
• Cytokine involvement in oocytes and early embryos.

  1991cited by this paper
• The pathogenesis of the ovarian hyperstimulation syndrome (OHS): a possible role for ovarian renin

  1991cited by this paper
• Modern management of ovarian hyperstimulation syndrome.

  1991cited by this paper
• Severe ovarian hyperstimulation syndrome: Role of peripheral vasodilation

  1991cited by this paper
• In vitro fertilization as a diagnostic and therapeutic tool in a patient with partial 17,20-desmolase deficiency.

  1991cited by this paper
• The effect of tumor necrosis factor on vascular smooth muscle. In vitro studies using rat aortic rings.

  1991cited by this paper
• The vascular endothelial growth factor family of polypeptides

  1991cited by this paper
• Lymphokines, including interleukin-2, alter gonadotropin-stimulated progesterone production and proliferation of human granulosa-luteal cells in vitro.

  1991cited by this paper
• Interleukin-6 administration has no acute hemodynamic or hematologic effect in the dog.

  1991cited by this paper
• Severe ovarian hyperstimulation syndrome and cerebrovascular accidents.

  1990cited by this paper
• Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor.

  1990cited by this paper
• Transcapillary fluid dynamics during ovarian stimulation for in vitro fertilization.

  1990cited by this paper
• Vascular endothelial growth factor is expressed in rat corpus luteum.

  1990cited by this paper
• Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis.

  1990cited by this paper
• Incidence of severe ovarian hyperstimulation syndrome after GnRH agonist/HMG superovulation for in-vitro fertilization.

  1990cited by this paper
• The potential relevance of cytokines to ovarian physiology: the emerging role of resident ovarian cells of the white blood cell series.

  1990cited by this paper
• Human follicular fluids contain tissue macrophages.

  1990cited by this paper
• The Ovarian Hyperstimulation Syndrome

  1990cited by this paper
• Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis.

  1989cited by this paper
• Vascular permeability factor, an endothelial cell mitogen related to PDGF.

  1989cited by this paper
• Interleukin-1 and its biologically related cytokines.

  1989cited by this paper
• Neurologic complications of captopril treatment of neonatal hypertension.

  1989cited by this paper
• The biology of interleukin-6.

  1989cited by this paper
• Multiple actions of interleukin 6 within a cytokine network.

  1988cited by this paper
• Interleukin-2: inception, impact, and implications.

  1988cited by this paper
• Blockage of ovulation by an angiotensin antagonist.

  1988cited by this paper
• Morphological studies of the microcirculatory system of periovulatory ovine follicles.

  1988cited by this paper
• Increased number of mast cells in the dominant follicle of the cow: relationships among luteal, stromal, and hilar regions.

  1987cited by this paper
• Sequential Changes in Plasma Luteinizing Hormone and Plasma Prorenin During the Menstrual Cycle

  1987cited by this paper
• Direct correlation between plasma renin activity and severity of the ovarian hyperstimulation syndrome.

  1987cited by this paper
• Relationship of gonadotropin-releasing hormone, danazol, and prostaglandin blockade to ovarian enlargement and ascites formation of the ovarian hyperstimulation syndrome in the rabbit.

  1986cited by this paper
• Plasma prorenin during early pregnancy: ovarian secretion under gonadotropin control?

  1986cited by this paper
• Infertility: Diagnosis and Management

  1985cited by this paper
• Cyclical secretion of prorenin during the menstrual cycle: synchronization with luteinizing hormone and progesterone.

  1985cited by this paper
• Renin-like activity in ovarian follicular fluid.

  1985cited by this paper
• Plasma prorenin in first-trimester pregnancy: relationship to changes in human chorionic gonadotropin.

  1985cited by this paper
• Clinical, endocrinologic, and intraovarian prostaglandin F responses to H-1 receptor blockade in the ovarian hyperstimulation syndrome: studies in the rabbit model.

  1984cited by this paper
• Asynchrony between human cumulus-corona cell complex and oocyte maturation after human menopausal gonadotropin treatment for in vitro fertilization.

  1984cited by this paper
• Absence of teratogenicity of indomethacin in ovarian hyperstimulation syndrome.

  1984cited by this paper
• Initiation of angiogenesis by human follicular fluid.

  1984cited by this paper
• Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid.

  1983cited by this paper
• Peritoneal Fluid Volume and 17β-Estradiol and Progesterone Concentrations in Ovulatory, Anovulatory, and Postmenopausal Women

  1982cited by this paper
• Origin of peritoneal fluid in women: an ovarian exudation product.

  1980cited by this paper
• ORIGIN OF PERITONEAL FLUID IN WOMEN: AN OVARIAN EXUDATION PRODUCT

  1980cited by this paper
• Biochemical characterization of peritoneal fluid in women during the menstrual cycle.

  1980cited by this paper
• Histamine Levels in Ovarian Hyperstimulation Syndrome

  1979cited by this paper
• Changes in volume, total protein and ovarian steroid concentrations of peritoneal fluid throughout the human menstrual cycle.

  1978cited by this paper
• Ovarian Hyperstimulation Syndrome: A Current Survey

  1978cited by this paper
• Ovarian hyperstimulation syndrome: a current survey.

  1978cited by this paper
• Demonstration of angiogenesis-activity in the corpus luteum of cattle.

  1977cited by this paper
• Treatment of Ovarian Hyperstimulation Syndrome by Antihistamine

  1976cited by this paper
• THE ROLE OF PROSTAGLANDINS IN OVARIAN HYPERSTIMULATION SYNDROME

  1976cited by this paper

• C-Phycocyanin ameliorates ovarian hyperstimulation syndrome by mitigating inflammation and enhances fertility in an OHSS mouse model.

  2026cites this paper
• Exploratory pilot trial of astaxanthin supplementation in PCOS patients at risk of OHSS with focus on RAGE-NFκB pathway.

  2026cites this paper
• Ovarian hyperstimulation syndrome following ovum pick-up procedure: A case study

  2025cites this paper
• The Therapeutic Potential of EGCG and Pro-EGCG in Mitigating Ovarian Hyperstimulation Syndrome: Unraveling the Modulatory Mechanism through the VEGF Pathway

  2025cites this paper
• Curcumin alleviates ovarian hyperstimulation syndrome in the rat model via inhibiting the nuclear factor kappa B/hypoxia-inducible factor-1α signaling pathway

  2025cites this paper
• Assessing and Addressing Cardiovascular and Obstetric Risks in Patients Undergoing Assisted Reproductive Technology: A Scientific Statement From the American Heart Association

  2025cites this paper
• Ovarian Mechanobiology: Understanding the Interplay Between Mechanics and Follicular Development

  2025cites this paper
• Chronic inflammation response as a key factor in polycystic ovary syndrome among patients with bipolar disorder.

  2025cites this paper
• Mendelian randomization study reveals causal associations between plasma metabolites, immune cell phenotypes, and ovarian hyperstimulation syndrome.

  2025cites this paper
• Recurrent failure of ART, thrombosis and thrombophilia

  2024cites this paper
• Ovarian Hyperstimulation Syndrome (OHSS): A Narrative Review and Legal Implications

  2024cites this paper
• Triggering oocyte maturation in IVF treatment in normal responders: a systematic review and network meta-analysis.

  2024cites this paper
• Calcium versus cabergoline for prevention of ovarian hyperstimulation syndrome: A systematic review and meta-analysis.

  2024cites this paper
• Efficacy of Dan’e Fukang Soft Extract in Moderate Ovarian Hyperstimulation Syndrome for Concurrent Treatment of Blood and Fluid Guided by the “Triple Prevention” Principle

  2024cites this paper
• The Implication of Mechanistic Approaches and the Role of the Microbiome in Polycystic Ovary Syndrome (PCOS): A Review

  2023cites this paper
• Iatrogenic Ovarian Hyperstimulation Syndrome in Late Luteal Phase – A Rare Case Report

  2023cites this paper
• Beyond the Umbrella: A Systematic Review of the Interventions for the Prevention of and Reduction in the Incidence and Severity of Ovarian Hyperstimulation Syndrome in Patients Who Undergo In Vitro Fertilization Treatments

  2023cites this paper
• Nintedanib Treatment After Ovulation is an Effective Therapeutic Strategy for the Alleviation of Ovarian Hyperstimulation Syndrome (OHSS) in a Mouse Model

  2022cites this paper
• Triggering with 1,500 IU of human chorionic gonadotropin plus follicle-stimulating hormone compared to a standard human chorionic gonadotropin trigger dose for oocyte competence in in vitro fertilization cycles: a randomized, double-blinded, controlled noninferiority trial.

  2022cites this paper
• Global Transcriptional Profiling of Granulosa Cells from Polycystic Ovary Syndrome Patients: Comparative Analyses of Patients with or without History of Ovarian Hyperstimulation Syndrome Reveals Distinct Biomarkers and Pathways

  2022cites this paper
• Severe ovarian hyperstimulation syndrome requiring recurrent large-volume paracenteses until 21 weeks’ gestation: a case report

  2022cites this paper
• Controlled ovarian hyperstimulation with gonadotropins for Clomiphene Citrate resistant Polycystic ovary syndrome leads to a higher risk of ovarian hyperstimulation syndrome

  2021cites this paper
• Oxidative stress status in severe OHSS patients who underwent long agonist protocol intracytoplasmic sperm injection cycles

  2021cites this paper
• A Histopathological Evaluation of Ovarian Hyperstimulation Syndrome on Reproductive and Vital Organs and the Role of the VEGF-PKA Pathway in a Mouse Model

  2021cites this paper
• Hyponatremia: An Untimely Finding in Ovarian Hyper-Stimulation Syndrome

  2021cites this paper
• Ovarian hyperstimulation syndrome and adverse pregnancy outcome: a systematic review and meta-analysis.

  2021cites this paper
• Association of metabolic and inflammatory markers with polycystic ovarian syndrome (PCOS): an update

  2021cites this paper
• Severe recurrent ascites in a Pseudo-Meigs’ syndrome variant

  2021cites this paper
• Risk factors for the development of endometrial fluid in women undergoing IVF: a retrospective cohort study.

  2021cites this paper
• Comparing the mannitol and albumin in management of the severe ovarian hyperstimulation syndrome (OHSS), a randomized clinical trial, with cost-effectiveness analysis

  2020cites this paper
• Plötzliche Belastungsdyspnoe bei einer jungen Frau – internistisch-gynäkologisches Grenzgebiet in der Notaufnahme

  2020cites this paper
• Prediction of severe ovarian hyperstimulation syndrome in women undergoing in vitro fertilization using estradiol levels, collected ova, and number of follicles

  2020cites this paper
• Inflammation and tissue homeostasis: the NF-κB system in physiology and malignant progression

  2020cites this paper
• Ovarian Hyperstimulation Syndrome

  2020cites this paper
• Association Between LH receptor Regulation and Ovarian Hyperstimulation Syndrome in a Rodent Model.

  2020cites this paper
• Insulin Resistance and Free Androgen as Predictors for Ovarian Hyperstimulation Syndrome in Non-PCOS Women

  2020cites this paper
• Platelet-derived growth factor B restores vascular barrier integrity and diminishes permeability in ovarian hyperstimulation syndrome.

  2020cites this paper
• A decision-making algorithm for performing or cancelling embryo transfer in patients at high risk for ovarian hyperstimulation syndrome after triggering final oocyte maturation with hCG

  2020cites this paper
• Transient receptor potential melastatin 2 ion channel activity in ovarian hyperstimulation syndrome physiopathology

  2020cites this paper
• Alterations of IL-1 and VEGF After Ischemia-Reperfusion Injured Uterus and Ovary in Rats

  2020cites this paper
• To curette or not to curette; efficiency of oocyte retrieval technique

  2020cites this paper
• Alterations of IL-1 and VEGF After Ischemia-Reperfusion Injured Uterus and Ovary in Rats.

  2020cites this paper
• Patients who failed to conceive following an in vitro fertilization cycle can be clustered into different failure causes using gene expression hierarchical analysis†

  2020cites this paper
• Effect of GnRH-antagonist, mifepristone and letrozole on preventing ovarian hyperstimulation syndrome in rat model.

  2020cites this paper
• Prevention and Management of Ovarian Hyperstimulation Syndrome

  2020cites this paper
• Repeated GnRH agonist doses for luteal support: a proof of concept.

  2019cites this paper
• Gene expression analysis of follicular cells revealed inflammation as a potential IVF failure cause

  2019cites this paper
• Is oocyte maturation rate associated with triptorelin dose used for triggering final oocyte maturation in patients at high risk for severe ovarian hyperstimulation syndrome?

  2019cites this paper
• Risk of spontaneous preterm labor in pregnancies achieved by in vitro fertilization and complicated with severe form of ovarian hyperstimulation syndrome: A case control study

  2019cites this paper
• Ovarian Hyperstimulation Syndrome

  2019cites this paper
• The Ovarian Hyperstimulation Syndrome.

  2018cites this paper
• Comparison of Cabergoline and Quinagolide in Prevention of Severe Ovarian Hyperstimulation Syndrome among Patients Undergoing Intracytoplasmic Sperm Injection

  2018cites this paper
• Ultrasound and hematological changes during early luteal phase in women at high risk for developing ovarian hyperstimulation syndrome

  2018cites this paper
• Rare genetic variants potentially involved in ovarian hyperstimulation syndrome

  2018cites this paper
• Concentration of soluble urokinase plasminogen activator receptor (suPAR) in the pre-ovulatory follicular fluid is associated with development of ovarian hyperstimulation syndrome during ovarian stimulation

  2018cites this paper
• Severe ovarian hyperstimulation syndrome modifies early maternal serum beta-human chorionic gonadotropin kinetics, but obstetrical and neonatal outcomes are not impacted.

  2017cites this paper
• Low-dose hCG as trigger day and 35 hr later have different ovarian hyperstimulation syndrome occurrence in females undergoing In vitro fertilization: An RCT

  2017cites this paper
• Effect of letrozole on moderate and severe early‐onset ovarian hyperstimulation syndrome in high‐risk women: a prospective randomized trial

  2017cites this paper
• Treatment of Ovarian Hyperstimulation Syndrome

  2017cites this paper
• Number of Oocytes Retrieved as a Criterion for “Freeze-All” Strategy versus a Single “Rescue” Bolus of Low-Dose Human Chorionic Gonadotropin Following GnRH Agonist for Ovulation Triggering: A Pilot Study

  2017cites this paper
• Severe ovarian hyperstimulation syndrome in a naturally conceived singleton pregnancy after ovulation induction: a case report.

  2017cites this paper
• Use of Mannitol Therapy for Ovarian Hyperstimulation Syndrome ( OHSS ) Management

  2017cites this paper
• Classification and Pathophysiology of Ovarian Hyperstimulation Syndrome

  2017cites this paper
• Volume expanders for the prevention of ovarian hyperstimulation syndrome.

  2016cites this paper
• The effect of luteal phase gonadotropin-releasing hormone antagonist administration on IVF outcomes in women at risk of OHSS

  2016cites this paper
• Ovarian Hyperstimulation Syndrome and Pregnancy

  2016cites this paper
• A case control study of stress and infertility in hypothyroid reproductive age group women residing in Udaipur, Rajasthan, India

  2016cites this paper
• Quinagolide compared with cabergoline in the prevention of ovarian hyperstimulation syndrome: a randomized trial

  2016cites this paper
• Pseudo-Meigs' syndrome secondary to metachronous ovarian metastases from transverse colon cancer.

  2016cites this paper
• A Rare Case of Acute Pseudo-Meigs' Syndrome Presenting with Pleural Effusion and Ascites and a Ruptured Leiomyoma and Hemorrhagic Shock

  2016cites this paper
• Electroacupuncture decreases the progression of ovarian hyperstimulation syndrome in a rat model.

  2016cites this paper
• Endokrinologische Notfälle in der Gynäkologie

  2016cites this paper
• Spontaneous Severe Ovarian Hyper Stimulation Syndrome Associated with Massive Pericardial Effusion and Hypothyroidism in Non-pregnant Woman

  2015cites this paper
• Attenuated AMH signaling pathway plays an important role in the pathogenesis of ovarian hyperstimulation syndrome.

  2015cites this paper
• Cabergoline for reducing ovarian hyperstimulation syndrome in assisted reproductive technology treatment cycles. A prospective randomized controlled trial.

  2015cites this paper
• Prevention of ovarian hyperstimulation syndrome in a rat model: comparison of the efficacy of tocilizumab with that of ranibizumab, cabergoline, and a gonadotropin-releasing hormone antagonist

  2015cites this paper
• Ovarian hyperstimulation syndrome: a clinical report on 4894 consecutive ART treatment cycles

  2015cites this paper
• Ovarian hyperstimulation syndrome

  2015cites this paper
• Severe ovarian hyperstimulation syndrome in spontaneous pregnancy treated successfully with cabergoline

  2015cites this paper
• Cabergoline administration prevents development of moderate to severe ovarian hyperstimulation syndrome and it contributes to reduction in ovarian volume

  2015cites this paper
• Cabergoline in Prevention of Ovarian Hyperstimulation Syndrome and Its Effect on Outcome In Intracytoplasmic Sperm Injection Cycles

  2014cites this paper
• Local VEGF inhibition prevents ovarian alterations associated with ovarian hyperstimulation syndrome.

  2014cites this paper
• Why we should transfer frozen instead of fresh embryos: the translational rationale.

  2014cites this paper
• Immunological and hemostasiological disorders in women with ovarian hyperstimulation syndrome

  2014cites this paper
• Follicular fluid placental growth factor is increased in polycystic ovarian syndrome: correlation with ovarian stimulation

  2014cites this paper
• Outpatient Management of Severe Ovarian Hyperstimulation Syndrome (OHSS) with Placement of Pigtail Catheter

  2014cites this paper
• Kinase insert domain receptor/vascular endothelial growth factor receptor 2 (KDR) genetic variation is associated with ovarian hyperstimulation syndrome

  2014cites this paper
• Alteration of endometrial receptivity in rats with ovarian hyperstimulation syndrome.

  2014cites this paper
• Pseudo‐Meigs' syndrome associated with hydropic degenerating uterine leiomyoma: A case report

  2014cites this paper
• Serum vascular endothelial growth factor levels following luteal gonadotrophin‐releasing hormone antagonist administration in women with severe early ovarian hyperstimulation syndrome

  2014cites this paper
• Alteration of endometrial receptivity in rats with ovarian hyperstimulation syndrome

  2014cites this paper
• A potential novel strategy, inhibition of vasopressin-induced VEGF secretion by relcovaptan, for decreasing the incidence of ovarian hyperstimulation syndrome in the hyperstimulated rat model.

  2014cites this paper
• Is severe OHSS associated with adverse pregnancy outcomes? Evidence from a case-control study.

  2014cites this paper
• The role of IL-6 trans-signaling in vascular leakage: implications for ovarian hyperstimulation syndrome in a murine model.

  2013cites this paper
• [Ovarian hyperstimulation syndrome: experience of a reproductive medicine center 2005-2011].

  2013cites this paper
• Impacto sobre la expresión génica del endometrio de la maduración final ovocitaria con un agonista de la GnRH y diferentes protocolos de soporte de fase lútea

  2013cites this paper
• Withdrawal of GnRH agonist decreases oestradiol and VEGF concentrations in high responders.

  2013cites this paper
• Immune activation in female infertility : Significance of autoantibodies and inflammatory mediators

  2013cites this paper
• Involvement of the ANGPTs/Tie-2 system in ovarian hyperstimulation syndrome (OHSS).

  2013cites this paper
• The Complication of a Treatment Approach: Ovaryen Hyperstimulation Syndrome (OHSS)

  2013cites this paper